About
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 931 investors are based in Palo Alto, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Palo Alto, US
Contact Information
Find more investors like Jazz
Search Investors